The Invesco Biotechnology & Genome ETF (PBE) was launched on 06/23/2005, and is a smart beta exchange traded fund designed to offer broad exposure to the Health Care ETFs category of the market. What ...

Amid the trying circumstances in the market right now, investors may be well served to target the best biotech ETFs to buy. Fundamentally, these exchange-traded funds benefit from permanent relevance.

Learn how LABD delivers -3x daily biotech exposure, why it’s down 99.98% since inception, and when it fits short-term trades.

The iShares Biotechnology ETF is up over 32% in six months on rate cut expectations and potential sector rotation. The State Street SPDR S&P Biotech ETF has surged 45% in six months but remains 27% ...

This was a new position; the IBB stake now accounts for 8.7% of Florin Court Capital LLP’s 13F AUM ICLN: $16.6 million (13.0% of AUM) IBB: $11.1 million (8.7% of AUM) IVW: $11.0 million (8.6% of AUM) ...

The State Street SPDR S&P Biotech ETF (XBI) was launched on January 31, 2006, and is a passively managed exchange traded fund designed to offer broad exposure to the Healthcare - Biotech segment of ...

This rally in Illumina proved a shot in the arm for one of the most Illumina-sensitive funds, the ARK Genomic Revolution ETF (BATS:ARKG). It surged about 4% this week to outperform broader biotech ...

There is no denying that the pandemic has opened up investment opportunities in the biotech sector by triggering a race to introduce vaccines and treatment options. Moreover, increasing mergers and ...

Shares Biotechnology ETF earns a reiterated hold rating as it consolidates near all-time highs with balanced risk/reward. Learn more about IBB ETF here.